Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2008
09/16/2008US7425218 Nitric oxide-releasing medical devices
09/16/2008CA2623858A1 Stabilized chlorine dioxide and hypochlorous acid in a liquid biocide
09/16/2008CA2515338C Inhibitors of histone deacetylase
09/16/2008CA2505128C Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
09/16/2008CA2480429C Novel therapeutical use of agonist ligands specific to g2a receptor
09/16/2008CA2472031C Medical device with coating that promotes endothelial cell adherence and differentiation
09/16/2008CA2447519C Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
09/16/2008CA2427221C Process and intermediates for preparing anti-cancer compounds
09/16/2008CA2414349C Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
09/16/2008CA2403949C Transdermal therapeutic system for the delivery of lerisetron
09/16/2008CA2384448C Method of treatment of seborrheic dermatitis
09/16/2008CA2379557C Arylsulphonamide-substituted benzimidazole derivatives, processes for preparing them and their use as pharmaceutical compositions
09/16/2008CA2378503C Manufacture and use of an antibiotic/antibiotics(or: antibiotic(s)) preparation
09/16/2008CA2378483C Crystalline 1-methylcarbapenem compounds
09/16/2008CA2373827C Endoparasiticidal synergistic combination containing cyclic depsipeptides and piperazines
09/16/2008CA2370501C Pharmaceutical composition for the therapy of lower urinary tract symptoms
09/16/2008CA2358498C The preparation and use of radium-223 to target calcified tissues for pain palliation, bone cancer therapy, and bone surface conditioning
09/16/2008CA2356422C Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
09/16/2008CA2348440C A method for supplying bioavailable methionine to a cow
09/16/2008CA2346062C Coated medicament forms with controlled active substance release
09/16/2008CA2339290C Reaction products of hyaluronic acid and natural amino acids and their use in cosmetic and pharmaceutical compositions
09/16/2008CA2337152C Pharmaceutical composition intended in particular for the prevention and the treatment of radiomucositis and chemomucositis
09/16/2008CA2331414C Transdermal therapeutic system for the administration of candesartan
09/16/2008CA2295483C Aliphatic propargylamines as cellular rescue agents
09/16/2008CA2294095C Synergistically acting compositions for selectively combating tumor tissue
09/16/2008CA2287477C Topical administration of catecholamines and related compounds to subcutaneous muscle tissue using percutaneous penetration enhancers
09/16/2008CA2273017C Local administration device for solid or semi-solid formulations, time-release formulations for parenteral administration and their method of preparation
09/16/2008CA2239519C Specific binding members for human carcinoembryonic antigen, materials and methods
09/16/2008CA2223910C Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (nhe), pharmaceutical methods and compositions employing such inhibitors, and processes for evaluating the nhe-inhibitory efficacy of compounds
09/16/2008CA2218120C Improved enzymatic synthesis of oligosaccharides
09/16/2008CA2215378C Diltiazem controlled release formulation
09/16/2008CA2188872C Physiologically acceptable emulsions containing perfluorocarbon ether hydrides and methods of use
09/16/2008CA2182228C Codrugs as a method of controlled drug delivery
09/16/2008CA2166062C The use of non-ionic surfactants in stable topical retinoid compositions
09/16/2008CA2123211C A method for assaying and treating alzheimer's disease
09/16/2008CA2120732C Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the cd2/lfa-3 interaction
09/12/2008WO2008109856A2 Methods of using diazepinone compounds in treating sodium channel-mediated diseases or conditions
09/12/2008WO2008109840A1 Tricyclic compounds useful in treating iron disorders
09/12/2008WO2008109837A2 Method for expression of small antiviral rna molecules with reduced cytotoxicity within a cell
09/12/2008WO2008109833A2 Polynucleotides and polypeptides identified by iviat screening and methods of use
09/12/2008WO2008109810A1 Use of glucosamine as a mental and physical stress recovery enhanced and performance enhancer
09/12/2008WO2008109780A1 Methods and compounds for the targeted delivery of agents to bone for interaction therewith
09/12/2008WO2008109737A1 Substituted phenoxy aminothiazolones as estrogen related receptor-alpha modulators
09/12/2008WO2008109730A1 Copper lowering treatment of inflammatory and fibrotic diseases
09/12/2008WO2008109727A1 Substituted phenoxy thiazolidinediones as estrogen related receptor-alpha modulators
09/12/2008WO2008109724A2 Treatment of cocaine-induced fetal brain injury
09/12/2008WO2008109719A2 Steroids derivatives as selective progesterone receptor modulators
09/12/2008WO2008109717A1 Compositions and methods for treating cancer
09/12/2008WO2008109702A1 Compounds and compositions as modulators of gpr119 activity
09/12/2008WO2008109700A1 Ppar active compounds
09/12/2008WO2008109697A2 Ppar active compounds
09/12/2008WO2008109614A1 9-chloro noscapine and its use in treating cancers, including drug-resistant cancers
09/12/2008WO2008109613A1 Benzo[c][2,7]naphthyridine derivatives, and their use as kinase inhibitors
09/12/2008WO2008109610A1 Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
09/12/2008WO2008109599A1 Pyrimido [5,4-c] quinoline-2, 4-diamine derivatives and methods of use thereof
09/12/2008WO2008109591A1 Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
09/12/2008WO2008109584A1 Hcv ns5b inhibitors
09/12/2008WO2008109560A2 Amelioration of cellular stress response
09/12/2008WO2008109556A1 Nucleic acid compounds for inhibiting telomerase gene expression and uses thereof
09/12/2008WO2008109551A1 Nucleic acid compounds for inhibiting tacstd1 gene expression and uses thereof
09/12/2008WO2008109547A2 Nucleic acid compounds for inhibiting tymp gene expression and uses thereof
09/12/2008WO2008109546A2 Nucleic acid compounds for inhibiting tgfbr gene expression and uses thereof
09/12/2008WO2008109544A1 Nucleic acid compounds for inhibiting muc1 gene expression and uses thereof
09/12/2008WO2008109534A1 Nucleic acid compounds for inhibiting ezh2 gene expression and uses thereof
09/12/2008WO2008109526A1 Nucleic acid compounds for inhibiting egr gene expression and uses thereof
09/12/2008WO2008109521A2 Method of treatment using atranorin
09/12/2008WO2008109518A1 Nucleic acid compounds for inhibiting wnt gene expression and uses thereof
09/12/2008WO2008109516A2 Nucleic acid compounds for inhibiting ras gene expression and uses thereof
09/12/2008WO2008109511A1 Nucleic acid compounds for inhibiting fcer2 gene expression and uses thereof
09/12/2008WO2008109506A1 Nucleic acid compounds for inhibiting jun gene expression and uses thereof
09/12/2008WO2008109494A1 Nucleic acid compounds for inhibiting stat3 gene expression and uses thereof
09/12/2008WO2008109492A1 Nucleic acid compounds for inhibiting igf1r gene expression and uses thereof
09/12/2008WO2008109475A1 Nucleic acid compounds for inhibiting sirt2 gene expression and uses thereof
09/12/2008WO2008109474A1 Nucleic acid compounds for inhibiting fgf2 gene expression and uses thereof
09/12/2008WO2008109473A1 Nucleic acid compounds for inhibiting abcb1 gene expression and uses thereof
09/12/2008WO2008109464A1 Spirolactam targeting compounds and related compounds
09/12/2008WO2008109462A2 Sustained release pellets comprising wax-like material
09/12/2008WO2008109461A1 Nucleic acid compounds for inhibiting cd3 gene expression and uses thereof
09/12/2008WO2008109454A2 Nucleic acid compounds for inhibiting fos gene expression and uses thereof
09/12/2008WO2008109449A1 Nucleic acid compounds for inhibiting bcl2 gene expression and uses thereof
09/12/2008WO2008109447A1 Nucleic acid compounds for inhibiting met gene expression and uses thereof
09/12/2008WO2008109437A2 Compositions comprising derivatives of 3 -phenylpyridazine for treating seizure-related disorders
09/12/2008WO2008109427A2 Anesthetic spray composition
09/12/2008WO2008109424A1 Composition, therapy and device for treatment of nail infections
09/12/2008WO2008109417A1 Mgmt inhibitor combinations for the treatment of neoplastic disorders
09/12/2008WO2008109382A1 Nucleic acid compounds for inhibiting pkn3 gene expression and uses thereof
09/12/2008WO2008109381A2 Nucleic acid compounds for inhibiting hif1a gene expression and uses thereof
09/12/2008WO2008109379A1 Nucleic acid compounds for inhibiting il17a gene expression and uses thereof
09/12/2008WO2008109376A1 Nucleic acid compounds for inhibiting bcr-abl gene expression and uses thereof
09/12/2008WO2008109375A2 Nucleic acid compounds for inhibiting pik3c gene expression and uses thereof
09/12/2008WO2008109373A1 Nucleic acid compounds for inhibiting erbb gene expression and uses thereof
09/12/2008WO2008109365A1 Nucleic acid compounds for inhibiting raf1 gene expression and uses thereof
09/12/2008WO2008109362A1 Nucleic acid compounds for inhibiting vegf gene expression and uses thereof
09/12/2008WO2008109361A1 Nucleic acid compounds for inhibiting erbb family gene expression and uses thereof
09/12/2008WO2008109360A1 Taxane analogs for the treatment of brain cancer
09/12/2008WO2008109359A1 Nucleic acid compounds for inhibiting pdgfr family gene expression and uses thereof
09/12/2008WO2008109357A1 Nucleic acid compounds for inhibiting apob gene expression and uses thereof
09/12/2008WO2008109356A1 Nucleic acid compounds for inhibiting tnfsf13b gene expression and uses thereof
09/12/2008WO2008109354A1 Nucleic acid compounds for inhibiting il18 gene expression and uses thereof
09/12/2008WO2008109352A2 Nucleic acid compounds for inhibiting akt gene expression and uses thereof
1 ... 3087 3088 3089 3090 3091 3092 3093 3094 3095 3096 3097 3098 3099 3100 3101 3102 3103 3104 3105 3106 3107 ... 7860